DYSIS Medical

DYSIS Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7M

Overview

DYSIS Medical is a forward-looking medtech company focused on transforming cervical cancer screening through its innovative computer-aided colposcopy technology. Founded in 2002, the company's FDA-cleared and CE-marked DYSIS Colposcope enhances the accuracy of lesion detection by providing an objective, color-coded map of the cervix. With strong clinical validation from over 5,500 exams, a favorable NICE recommendation in the UK, and adoption in both private practices and public health systems, DYSIS is positioned to improve standard-of-care in a critical area of women's health.

OncologyWomen's Health

Technology Platform

Dynamic Spectral Imaging (DSI) platform that objectively quantifies the dynamics of acetowhitening in cervical tissue during colposcopy, producing a color-coded map (DYSISmap™) to guide biopsy placement and lesion detection.

Funding History

2
Total raised:$7M
Series A$5M
Seed$2M

Opportunities

Growth opportunities include expanding adoption within the UK's NHS following its 'recommended' status from NICE, penetrating the large US private practice market, and leveraging its Dynamic Spectral Imaging platform for potential future applications in detecting other epithelial pre-cancers.
Continued publication of real-world evidence can drive further clinical consensus and adoption.

Risk Factors

Key risks include slow adoption rates due to the need to change clinical practice and replace existing colposcopes, reimbursement challenges in key markets outside the UK, emerging competition from AI-based software solutions that work with standard colposcopes, and reliance on a single product platform without a diversified pipeline.

Competitive Landscape

DYSIS competes with traditional colposcope manufacturers (Leisegang, Olympus) and newer digital/adjunctive technology companies like MobileODT. Its key differentiation is its FDA-cleared and NICE-recommended technology that objectively measures the dynamic acetowhitening process, providing an integrated hardware-software solution designed to improve diagnostic accuracy within the standard clinical workflow.